Exploring the role of myonectin in heart attack recovery
Assessing the Relationship Between Myonectin Concentration and the Course of Hospitalization and the 30-day Risk of Cardiac Endpoints in Patients With the First Incident of ST-segment Elevation Mycardial Infarction Treated With Primary PCI
This study looks at whether higher levels of myonectin can help people recover better after their first heart attack and how it relates to their diet, activity level, and heart health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Wojewodzki Szpital Zespolony w Elblagu Academic / other |
| Locations | 1 site (Elblag, Warmian-Masurian Voivodeship) |
| Trial ID | NCT05700773 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between myonectin concentration and the recovery of patients experiencing their first ST elevation myocardial infarction (MI) treated with primary percutaneous coronary intervention (PCI). It aims to determine if higher levels of myonectin can positively influence in-hospital and 30-day outcomes following the MI. Additionally, the study will explore how myonectin levels relate to patients' nutritional status, physical activity, and various cardiac biomarkers, with a focus on long-term mortality and myocardial infarction extent. The findings could provide insights into the potential protective role of myonectin in heart attack scenarios.
Who should consider this trial
Good fit: Ideal candidates include individuals experiencing their first ST elevation myocardial infarction and undergoing primary PCI.
Not a fit: Patients with a history of myocardial infarction, significant heart failure, or those unable to cooperate due to altered consciousness may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could identify myonectin as a valuable prognostic indicator and therapeutic target for improving outcomes in heart attack patients.
How similar studies have performed: While the protective properties of myonectin have been observed in animal studies, this approach has not been previously tested in humans.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * symptoms of acute coronary syndrome * acute ST segment elevation in two or more leads in ECG * primary PCI Exclusion Criteria: * pregnancy * patients unconscious, with altered consciousness or not able to cooperate * cardiogenic shock * significant physical effort within 24 hours before onset of MI * active infection at admission, intramuscular injection * myocardial infarction in patient's medical history * heart failure New York Heart Association (NYHA) class III - IV in patient's medical history * renal failure (chronic kidney disease, CKD) with glomerular filtration rate (GFR) \< 30ml/min * history of malignant neoplasms in the last 5 years * patients incapacitated, active soldiers, imprisoned or related with investigators
Where this trial is running
Elblag, Warmian-Masurian Voivodeship
- Voivodeship Hospital in Elblag — Elblag, Warmian-Masurian Voivodeship, Poland (Recruiting)
Study contacts
- Principal investigator: Michał Jaśkiewicz, MD — Voivodeship Hospital in Elblag, Poland; Department of Cardiology
- Study coordinator: Michał Jaśkiewicz, MD
- Email: mich.jask@gmail.com
- Phone: +48 606613129
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.